Skip to main content
OpenTrials
Completed

NCT Number: NCT01585792

Double Blind Comparative Study of TAK-875

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Patients

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Fukuoka, Japan

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The participant is an outpatient.
  • The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

  • The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
  • The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Treatment and study plan

TAK-875

Drug

Glimepiride

Drug

Placebo

Drug

Primary outcomes

  1. Blood glucose

    Time frame: 4 weeks

    Blood glucose

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Apr 26, 2012
Registry last updated
Apr 16, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.